Publication & Citation Trends
Most Cited Works
Publications
59 total
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial
Cited by 29
OpenAlex
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial
Cited by 31
OpenAlex
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma PDF
Cited by 3,338
OpenAlex
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
Cited by 126
OpenAlex
Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients
Cited by 26
OpenAlex
Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group
Cited by 25
OpenAlex
Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study
Cited by 20
OpenAlex
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France PDF
Cited by 23
OpenAlex
Research Topics
Renal cell carcinoma treatment
(14)
Cancer Immunotherapy and Biomarkers
(9)
Bladder and Urothelial Cancer Treatments
(9)
Head and Neck Cancer Studies
(8)
Prostate Cancer Treatment and Research
(6)
Frequent Co-Authors
Affiliations
Université Claude Bernard Lyon 1
Université de Tours
Inserm
Lyon College
Institut Gustave Roussy